Rearrangements of the upstream regulatory region of ... - CiteSeerX

4 downloads 32 Views 3MB Size Report
cous carcinomas differ from HPV-6b isolated from a benign genital wart, by ..... papillomavirus in verrucous carcinoma (Ackermann) of the vagina. Archives of ...
Journal of General Virology (1992), 73, 3147-3153.

Printed in Great Britain

3147

Rearrangements of the upstream regulatory region of human papillomavirus type 6 can be found in both Buschke-L6wenstein tumours and in condylomata acuminata Albert Riibben, 1. Sylvie Beaudenon, 2 Michel Favre, 2 Wolfgang Schmitz, 1 Bettina Spelten I and Elke-Ingrid Grussendorf-Conen 1 I Hautklinik (Department o f Dermatology) der R WTH-Aachen, Pauwelsstrasse 30, 5100 Aachen, Germany and 2Unitb des Papillomavirus, Unitk de l'Institut National de la Sant~ et de la Recherche Mkdicale 190, Institut Pasteur, 75015 Paris, France

Clinically malignant Buschke-L6wenstein tumours and benign condylomata acuminata are caused by human papillomaviruses (HPVs), predominantly HPV-6 and -11. In some cases, the HPV-6 genomes found in Buschke-L6wenstein tumours and in verrucous carcinomas differ from HPV-6b isolated from a benign genital wart, by rearrangements of the upstream regulatory region (URR). To evaluate the frequency and role of mutations of the U R R of HPV-6 we analysed 42 condylomata acuminata and four BuschkeL6wenstein tumours by the polymerase chain reaction and restriction enzyme cleavage. Using only four different restriction enzymes we could demonstrate

four distinct restriction patterns, indicating that naturally occurring HPV-6 isolates display a high degree of D N A polymorphism within the URR. One BuschkeL6wenstein tumour and two condylomata acuminata yielded rearranged U R R s with D N A duplications. All three lesions harboured multiple HPV-6 variants, suggesting that cellular or environmental factors facilitate the development of rearrangements. Therefore, rearrangements of the U R R may represent only secondary events in condylomata acuminata and Buschke-L0wenstein tumours which do not necessarily confer a higher malignant potential to the infected cell.

Introduction

1986), low grade carcinomas of the vagina and larynx (Okagaki et al., 1984; Rando et al., 1986a, Sutton et al., 1987), and primary carcinoma of the urethra (Grussendorf-Conen et al., 1987). All HPV types share a similar genomic structure consisting of a late region encoding structural proteins and an early region encoding proteins involved in replication and in the regulation of transcription of viral genes, and in immortalization and transformation of infected cells. An upstream regulatory region (URR) [synonyms: non-coding region (NCR) or long control region] of 500 to 1000 bp is situated between the late and early genes. The U R R contains various enhancer and promoter elements which play an important role in the regulation of viral gene expression and virus-host cell interaction (Pfister, 1990). Analysis of the U R R in HPV-6-induced tumours has led to the identification of HPV-6 variants with rearranged URRs. Duplications within the 3' portion of the U R R have been found in a benign and in an atypical condyloma acuminatum (Kulke et al., 1989; Wu &

Human papillomaviruses (HPVs), of which over 66 types have been identified, are associated with a wide range of epithelial tumours in man. Clinically, HPV types differ mainly in tissue specificity and oncogenic potential. Of the HPV types predominantly infecting mucosa, HPV-6 and -11 are associated mainly with benign condylomata acuminata and laryngeal papillomas (Gissmann & zur Hausen, 1980; Gissmann et al., 1982, 1983), whereas HPV-16 and -18 are strongly associated with cervical intraepithelial neoplasias and cervical cancer (Boshart et al., 1984; Diirst et al., 1983). Therefore HPV-6 and -11 are considered to be low risk viruses for malignant transformation of infected tissue (zur Hausen & Schneider, 1987). Nevertheless, in several cases it has been demonstrated that carcinomas may arise within condylomata acuminata (Grussendorf & Gahlen, 1974, Grussendorf & B/ir, 1977), and HPV-6 and -11 have been detected in clinically malignant Buschke-I_6wenstein tumours (Gissmann et al., 1983; Boshart & zur Hausen, 0001-1247 © 1992 SGM

3148

A . Ri~bben a n d others

Mounts, 1988), and in a Buschke-L6wenstein tumour (Boshart & zur Hausen, 1986). A large head-to-tail duplication of the URR, the late region and a portion of the early region has recently been identified in a squamous lung carcinoma (DiLorenzo et al., 1992). It has been demonstrated by chloramphenicol acetyltransferase assay that duplicated sequences within the URR could produce enhancer functions (Wu & Mounts, 1988). This has led to the hypothesis that duplications of the URR might raise the otherwise low oncogenic potential of HPV-6 by enhancing transcription of transforming genes E6 and E7. Rearrangements within the 5' portion of the URR of HPV-6 have been found in two squamous carcinomas of the vulva (Kasher & Roman, 1988; Rando et al., 1986a). In one case (Rando et al., 1986b) the rearranged URR seemed to constitute a stronger enhancer than the analogous region from HPV-6b, but this finding could not be reproduced in the second case (Farr et al., 1991). Duplications within the URR have also been detected in laryngeal carcinomas associated with HPV-11 (Byrne et al., 1987), and in anogenital carcinomas containing HPV-16 (Di Luca et al., 1989, Scheurlen et al., 1986) and HPV-33 (Cole & Streeck, 1986). Despite the interesting implications of these findings, no epidemiological data have been published on the frequency of mutations and rearrangements within the URR of HPV-6 in condylomata acuminata and BuschkeLfwenstein tumours. Rearranged HPV-6 genomes should predominate in histologically or clinically more malignant lesions if they confer a stronger malignant potential on HPV-6. Epidemiological data would also indicate whether rearranged HPV-6 variants represent naturally occurring viruses which might constitute an important risk factor for the infected patient. The aim of this study was to evaluate the frequency and type of mutations within the URR of HPV-6 in condylomata acuminata and Buschke-L6wenstein tumours in the general population.

Methods Patients and specimens. Tissue specimens were obtained from patients attending the Department of Dermatology of the RWTHAachen; 47 patients had anogenital condylomata acuminata and four had Buschke-L6wenstein tumours. After surgical removal, one part of each specimen was stored frozen at - 20 °C and one portion was fixed in formalin and embedded in paraffin for histological examination. Large specimens were divided into equal smaller portions which were analysed separately. DNA was extracted from biopsies as described (Orth et aL, 1980). Polymerase chain reaction (PCR). Amplifications were performed as described by Saiki et al. (1985). The following two primer pairs were used to amplify the U R R of HPV-6. URR1/2 [nucleotides (nt) 6487 to 320 of the published HPV-6b sequence (Schwarz et al., 1983)]: sense

bp

M

la

lb

lc

2

3

4

5

6

7

8

M

M

9

10

11

12

13

14

15

16

17

18

M

M

19 20

21

22

23

24

25

26

M

28

30

31

32

33

1988--~ 1848--~

M

38

29

39

40

41

42

34

43

35

36

44

27 M

37

45

M

46

Fig. 1. PCR-mediated amplification with primer pair URR1/2 of HPV-6 DNA obtained from specimens I to46. Lanes M, 142 bp ladder.

strand: 5' G G C T G C A G A C C C A T A T G G T G Y, antisense strand 5' TTTTCCATGAAATTCTAGGCAGC 3'; URR3/4 (nt 7446 to 284): sense strand 5' G C T G T T G C A C G C G T T T T G G T 3', antisense strand 5' A T A T G G A T A G C C G C C T C G A A 3'. Amplification with primer pair URR1/2 was performed with 20 cycles of 1 min denaturation at 92 °C, 1 rain annealing at 55 °C and 2 min extension at 72 °C, followed by 15 cycles of 1 min denaturation at 92 °C, 1 min annealing at 55 °C and 2-5 min extension at 72 °C. Elongation time during the last 15 cycles was prolonged to favour the amplification of long DNA sequences. Amplification with primer URR3/4 was performed with 35 cycles of I min denaturation at 92 °C, 1 min annealing at 55 °C and 1-5 min extension at 72°C. Both programmes terminated with an extension step of 7 min duration. PCR products were separated on 1.0~ agarose gels in Tris-borate-EDTA and stained with ethidium bromide.

Restriction enzyme cleavage experiments. Analysis of PCR products by restriction endonuclease digestion was performed to compare the resulting restriction patterns with the published sequence of HPV-6b (Schwarz et al., 1983). RsaI (Pharmacia), DdeI (Pharmacia), PstI (Boehringer Mannheim), HpalI (Pharmacia), and HaelI (Pharmacia) and HaelII (Pharmacia) (1 unit of each) were used for cleavage after ethanol precipitation of PCR products and resuspension in water. Double digestions were performed to determine restriction maps. DNA fragments were separated on 1.5~ agarose gels. Southern blot hybridization. The sample DNAs (5 to 10 ~tg) were digested with PstI, electrophoretically separated in 1 ~ agarose slab gels (Agarose NA; Pharmacia), denatured and transferred to nitrocel-

Rearrangements of the URR of HPV-6 lb

Ic

9

13

kh

1

2

3

Fig. 2. PCR-mediated amplification with primer pair URR3/4 of HPV-6 D N A obtained from specimens tb, lc, 9 and 13.

lulose membranes (Hybond-C; Amersham). The membranes were hybridized with a 32p-labelled HPV-6 probe under stringent conditions (Tin -- 10 °C).

Results PCR and Southern blot analysis of the URR The PCR with primer pair URR1/2 detected HPV-6 D N A sequences in all Buschke-L6wenstein tumours (specimens la to 4) and in biopsies from 42 patients of 47 with condylomata acuminata (specimens 5 to 46). PCR with primer pair U R R 1/2 amplified part of L 1, the entire U R R of HPV-6 and part of E6. Sequence data from HPV-6b predicted a PCR product of 1735 bp (Schwarz et al., 1983). Electrophoresis and ethidium bromide staining of amplified products obtained from specimen D N A showed a predominant band of approx. 1850 bp (Fig. 1). One large Buschke-L6wenstein tumour was divided into three portions (la to lc). PCR products from two portions (lb and lc) showed additional bands of greater molecular size (approx. 2070 and 2450 bp). Specimen 9 yielded two additional bands of approx. 1870 and 2000 bp, and specimen 13 showed an enlarged amplification product of approx. 1960 bp. For further characterization of the enlarged and additional HPV-6 D N A species in specimens lb, lc, 9 and 13, primer pair URR3/4 was designed to amplify the 3' portion of the U R R and part of E6 (Fig. 2). Blotting of the PCR products and hybridization with a subgenomic HPV-6 probe (nt 7438 to 7863) confirmed the amplification of HPV-6 D N A sequences (data not shown). Sequence data from HPV- 6b predicted a PCR product of 740 bp. Analysis of the Buschke-L~Swenstein tumour of patient 1 showed the presence of additional bands of

3149

!

0.6----~

"

::~ :

Fig. 3. Southern blot analysis of total cell D N A digested with PstI and hybridized with HPV-6 DNA. Lanes 1, 2 and 3, extracted total cell D N A from specimens la, lb and lc.

approximately 980 and 1360 bp in specimens lb and lc (Fig. 2). The difference in length from the amplified sequence from specimen la (760 bp) was 220 and 600 bp, respectively, and was equivalent to the results obtained with primer pair URR1/2. A Southern blot with the extracted total cell D N A obtained from specimens 1a, 1b and lc confirmed that the Buschke-L6wenstein tumour of patient 1 contained three HPV-6 D N A species differing in the length of the URR, and that these DNAs were unevenly distributed in the tumour (Fig. 3). Specimen 1a (lane l) showed fragments corresponding to HPV-6a DNA (approx. 3.7, 1.7, 1.5, 1.1 kbp). The HPV6 D N A in specimen la was named AC1A. Specimen lb contained an additional band of approx. 1.9 kb (lane 2). The difference in size from the 1.7 kb fragment containing the U R R corresponded to the size difference of approx. 220 bp demonstrated by PCR. The enlarged HPV-6 D N A present in specimen lb was named AC1B. Specimen lc (lane 3) showed an additional fragment of 0-6 kb, confirming the size difference found by PCR. The enlarged D N A species was named AC1C. PCR-mediated D N A amplification of D N A from specimen 9 with primer pair URR3/4 revealed three products of approx. 740, 790 and 920 bp (Fig. 2). The difference in length between the PCR products was equivalent to the difference found by amplification with primer pair URR1/2. The HPV-6 D N A in the condyloma acuminatum of patient 9 yielding a U R R of normal size was named AC9A. The HPV-6 D N A with a U R R

3150

bp 830 730 640 610

A. Rftbben and others

1

2

3

4

5

6

7

8

9

H3 H3

nt 6487 ] HPV-6b [-

10

H2

D R

L1 ACV1

~-

IIIIit

E

!l I!!!

ACV3 U ~ ~ - I / l l l l 400

IB IIivl

305

ACV4

205

AC27

E

II t / l t l l t

I

II IkIv1

I[[f

25-

(b) 2

3

2

3

4

5

6

7

8

9

10

(c) 1

Ill

I ! ~ R

JI III

/

20 bp

I t

rl ff f_ r

+ 20 bp

rrvr t

i

+ 20 bp

r

Fig. 5. Restriction maps of amplified HPV-6 DNAs between nt 6487 and 320. R, RsaI; D, DdeI; H2, HaelI; H3, HaeIII. DNA insertions and additional restriction sites are given approximate locations. Restriction sites differing from those of HPV-6b are indicated by arrows.

90 65.

1

+ 20 bp

¢11y~L_

+ 10t1 bp

If

n t 320

E6

+ 90 bp

+ 80 bp

150

t

+ 100 bp

H3

D

NCR + 100 bp

ACV2

H2

4

5

6

7

8

9

enlarged by approx. 50 bp was termed AC9B; AC9C is the HPV-6 D N A species with the largest U R R . Analysis of specimen 13 with primer pair U R R 3 / 4 demonstrated the presence of an enlarged band of 880 bp, corresponding to the 1960 bp product obtained with primer pair URR1/2. The enlarged HPV-6 D N A responsible for this P C R product was named AC13A. Furthermore, P C R with URR3/4 showed two additional amplified products of approx. 760 (weak band) and 1100 bp (Fig. 2) which were not observed with primer pair URR1/2. Unfortunately, specimens 9 and 13 did not yield enough D N A to allow the demonstration of enlarged fragments by Southern blot analysis of total cell DNA.

10 Restriction fragment length polymorphism o f the URR

Fig. 4. Restriction enzyme cleavage of PCR product obtained using URR1/2 with RsaI (a), DdeI (b) and HaelI + HaelII (c). Lanes 1, ACV1; lanes 2, ACV2; lanes 3, ACV3; lanes 4, ACV4; lanes 5, specimen la; lanes 6, specimen lc; lanes 7, specimen lb; lanes 8, specimen9; lanes 9, specimen 13; lanes 10, specimen27. Additionalor enlarged bands are indicated by arrowheads, a, double bands.

P C R products of all specimens obtained with primer pair URR1/2 were examined by cleavage with RsaI or DdeI, and by double digestion with HaelI and HaelII to compare the resulting restriction maps to that of the published HPV-6b D N A sequence. Analysis by agarose gel electrophoresis allowed estimation of the size of the fragments to approx. 10 bp accuracy. Five variants could be distinguished (Fig. 4 and 5, Table 1). Twenty-two condylomata acuminata and three Buschke-I_6wenstein tumours showed the predominant variant A C V ! which differed from the homologous D N A sequence of HPV6b by the absence o f a DdeI site at nt 7565 of the HPV-6b D N A sequence, by an insertion of approx. 100 bp between the RsaI site at nt 7331 and the DdeI site at nt 7440, and by an insertion of approx. 20 bp between the HaelI site at nt 7696 and the DdeI site at nt 7843. Ten condylomata acuminata yielded variant ACV2 which differed from the D N A sequence of HPV-6b by an

Rearrangements of the URR of HPV-6 Table 1. Frequency of subtypes detected by restriction enzyme cleavage of PCR product NCR1/2

HPV-6b

T44e

~

D R H2 t i I

~

HP D [ I I

Diagnosis Type ACV1 ACV2 ACV3 ACV4 AC27 Total Duplication

Condyloma acuminatum

3 1 4 1I"

* Both ACV2. i" ACVI.

insertion of approx. 90 bp between the RsaI site at nt 7331 and the DdeI site at nt 7440. Variant ACV3 was detected in four condylomata acuminata and one Buschke-L6wenstein tumour. ACV3 differed from ACV1 by an additional RsaI site at approx, nt 7830. Five condylomata acuminata showed variant ACV4, which differed from ACV1 only by an additional HaelII site at approx, nt 6700. HPV-6 D N A from specimen 27, a condyloma acuminatum, showed a different pattern characterized by a missing DdeI site at nt 7565, by an insertion of approx. 80 bp between the RsaI site at nt 7331 and the DdeI site at nt 7440, and by an insertion of approx. 20 bp between the HaelI site at nt 7696 and the DdeI site at nt 7843 (AC27) (Fig. 4 and 5). All isolates yielding enough DNA demonstrated the PstI cleavage pattern of HPV-6a by Southern blot analysis.

Characterization of rearranged HP V-6 variants Restriction fragment analysis of the amplified products obtained with primer pair URR1/2 demonstrated that the increases in size of DNAs AC1B, AC1C, AC9B, AC9C and AC13A were due to rearrangements in the 3' portion of the U R R (Fig. 4). For further characterization of the enlarged HPV-6 DNAs, the amplified products obtained with primer pair URR3/4 were examined by cleavage with RsaI, DdeI, HaelI, HpalI and PstI. AC1B contained an insertion of approx. 220 bp between the HaelI site at nt 7696 and the PstI site at nt 224 (Fig. 6), and ACIC showed an insertion of approx. 600 bp between the primer-binding sites of URR3/4. Sequencing of the U R R of AC1B and AC1C demonstrated exact tandem duplications of 218 bp (nt 7707 to 2) and 592 bp (nt 7586 to 255) (Fig. 6). The 20 bp insertion found in isolates AC1A, AC1B and AC1C could be identified as the 20 bp insert at nt 7720 already described by Kulke et al. (1989). AC9B contained an insertion of approx. 50 bp between the HaelI site at nt 7696 and the DdeI site at nt

ACIB

~

.t2e4

.

I

HP

HP

Buschke-I.fwenstein tumour

22 10 4 5 1 42 2*

ATG ~

• 21abp ~

]

Duplication nt 7707 to 2 "P A~G AC1C

~ ~

D

AC9B

I

.

AC9C

~

R

D

R.2

HP

• 692 b. ~ Duplication nt 7586 to 255 HP H2 D~ A; G p,

50 bp ~ - leo bo R H2

H2

3151

^TG 1

I

~

[ OHP

ATG

p

Fig. 6. Restrictionmaps of amplifiedHPV-6DNAs betweennt 7445 and 284. R, RsaI; D, DdeI; H2, I-IaeII; HP, /-/pail; P, PstI. DNA insertions and additional restriction sites are given approximate locations.Bindingsitesforthe E2 protein(E),glucocorticoids(G),NF 1 (N) and AP1 (A) are indicated by boxes.

7843 (Fig. 6). The larger DNA species, AC9C, from the same specimen showed an insertion of 180 bp between the RsaI site at nt 7633 and the DdeI site at nt 7863. AC13A demonstrated an insertion of 140 bp in the same region. In both cases the HaeII site at nt 7696 was duplicated, suggesting DNA duplications within the 3' portion of the URR.

Discussion PCR analysis of the U R R of HPV-6 in 42 condylomata acuminata and four Buschke-L6wenstein tumours demonstrated a high degree of D N A polymorphism within the URR. By comparison of restriction fragments generated with only four enzymes we could distinguish four variants of HPV-6 with differences within the URR, and one variant with an additional restriction site within L1. Two regions within the U R R of HPV-6 frequently differed from the HPV-6b sequence. All our specimens showed insertions of approx. 80 to 100 bp between the RsaI site at nt 7331 and the DdeI site at nt 7440. Boshart & zur Hausen (1986) have reported that the HPV-6b clone used for sequence analysis contains a deletion of approx. 120 bp in this region owing to a cloning artefact. The previously described variants HPV-6vc (Rando et al., 1986a), HPV-6e, HPV-6g (Wu & Mounts, 1988), HPV-6-T70 and HPV-6-W50 (Kasher & Roman, 1988) all show insertions in this region. Sequencing will show whether the 80 to 100 bp inserts found in the HPV-6 isolates are similar to these. It is worth stressing that

3152

A. Ri~bben and others

differences in this region allowed the identification of three variants, thus indicating high variability of the 5" portion of the URR among naturally occurring HPV-6 isolates (Fig. 5). A second region which frequently differed from the sequence of HPV-6b is located between the HaeII site at nt 7696 and the DdeI site at nt 7843. Of 46 patients, 36 harboured an HPV-6 isolate with an insertion of approx. 20 bp, most probably representing the 20 bp insertion at nt 7720 found in HPV-6ma, isolated by Kulke et al. (1989). Four variants could be characterized by differences within these two regions and they seem to account for the natural diversity between HPV-6 isolates. Correlation of the variants with the histology and location of lesions did not produce any significant differences. Therefore epidemiological data suggest that biological differences between these variants are either absent or concealed by more prominent differences between the hosts. This view is consistent with the results of Farr et al. (1991) who found similar enhancer activity and transforming potential in HPV-6T70 and HPV-6-W50. The putative and confirmed duplications in the 3' portion of the URR found in one of four BuschkeLfwenstein tumours and two of 42 condylomata acuminata seem to constitute a totally different entity. Although all duplications in our study were situated in the 3' portion of the URR no two duplications were the same. The same applies to variants identified previously. Wu & Mounts (1988) described HPV-6g, originating from a benign condyloma acuminatum, as having a 136 bp duplication encompassing nt 7719 to 7846; Kulke et al. (1989) isolated HPV-6ma from an atypical condyloma acuminatum and found it to contain a duplication within the URR of 236 bp between nt 7681 and 7896; Boshart & zur Hausen (1986) analysed a Buschke-Ltwenstein tumour and found a 459 bp duplication between nt 7528 and nt 84 (HPV-6d). The unique character of the duplications found in the 3' portion of the URR suggests that these variants represent the result of single rearrangements rather than naturally occurring viruses. Nevertheless, the fact that the reported duplications are all localized in the 3' portion of the URR deserves further discussion. The 3' portion of the URR could either be more susceptible to rearrangements than the coding sequences or its function could be less disturbed by duplications. The persistence of rearranged variants in a lesion may reflect a higher fitness of the virus, which may be linked to an enhanced malignant potential. On the other hand, clonal expansion of an infected cell due to alteration of cellular genes may lead to the predominance of a rearranged HPV-6 variant which is independent of virus fitness or the transforming potential of the virus. Our finding of two condylomata acuminata of normal appearance bearing putative DNA duplications indi-

cates that rearrangements are not restricted to HPV-6induced lesions expressing a more malignant phenotype, although these lesions may progress at later stages. Up to now, HPV-6 variants bearing duplications within the 3' portion of the URR have been found in four cases of condyloma acuminatum (HPV-6g, HPV-6ma, HPV-6AC9B and HPV-6-ACI3A) and only two cases of Buschke-Ltwenstein tumour (HPV-6d and HPV-6ACIB,C). This might be a further argument against duplication of the URR having a significant role in carcinogenesis. Moreover, eight of 10 Buschke-Ltwenstein tumours analysed (Boshart & zur Hausen, 1986 and our data) provide no evidence for structural alterations in the URR of HPV-6 and HPV-11. Nevertheless, taking into account the rarity of Buschke-Ltwenstein tumours in the general population, one might argue that the relative frequency of structural rearrangements within the 3' portion of the URR of HPV-6 is higher in BuschkeLfwenstein tumours than in condylomata acuminata. Our study also demonstrates that all three lesions containing HPV-6 variants with a rearranged URR have HPV-6 DNA of lower molecular size and additional rearranged HPV-6 variants. This indicates that the HPV-6 variants initially infecting the tissue most probably did not contain rearrangements within the URR. These HPVs are represented by isolates AC1A and AC9A showing variants ACV1 and ACV2, which are frequent in the condylomata acuminata. Isolates AC1B and AC1C, and AC9B and AC9C differ from isolates AC1A and AC9A only by duplications. They are most probably the result of subsequent mutations during tumour growth. A similar coexistence of two HPV-6 DNA species in one lesion has recently been observed in a lung carcinoma (DiLorenzo et al., 1992). The uneven distribution of isolates AC 1B and AC1C in the BuschkeLtwenstein tumour of patient 1 can be explained by rearrangements occurring at different locations and times. The finding of multiple rearranged variants in all three lesions suggests that these lesions either facilitated the occurrence of rearrangements within the URR or the survival of rearranged HPV-6 DNA. The existence of cellular or environmental factors favouring viral rearrangements is speculative, but should nonetheless be considered. The epidemiological data obtained could not demonstrate a clear correlation between genomic rearrangements and malignant potential of HPV-6. Host factors are probably responsible for most Buschke-Ltwenstein tumours and rearrangements in the 3' portion of the URR may represent only secondary events in condylomata acuminata and Buschke-Ltwenstein tumours which do not necessarily confer a higher malignant potential to the infected cell. Experiments to determine the enhancer activity and the transforming potential of

Rearrangements of the URR of HPV-6 the rearranged HPV-6 variants found in the BuschkeL6wenstein tumour and the condylomata acuminata are in progress. We thank G6rard Orth for kindly giving us the opportunity of carrying out the Southern blot experiments in his laboratories. We also thank Patricia Flamant and G&ard P6hau-Arnaudet for technical assistance. The research was supported by grant W 62/90/Gr 2 from the Deutsche Krebshilfe.

References BOSHART,M. & ztm HAUSEN,H. (1986). Human papillomaviruses in Buschke-l.~wenstein tumours: physical state of the DNA and identification of a tandem duplication in the noncoding region of a human papillomavirus 6 subtype. Journal of Virology 58, 963-966. BOSHART,M., GISSMANN,L., IKENBERG,H., KLEINHEINZ,A., SCHEURLEN, W. & ZUR HAUSEN,H. (1984). A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO Journal 3, 1151-1157. BYRNE, J. C., TSAO, M.-S., FRASER, R. S. & HOWLEY, P. M. (1987). Human papillomavirus-11 DNA in a patient with chronic-laryngotracheobronchial papillomatosis and metastatic squamous-cell carcinoma of the lung. New England Journal of Medicine 317, 873-878. COLE, S. T. & STREECK, R. E. (1986). Genome organization and nucleotide sequence of human papillomavirus type 33, which is associated with cervical cancer. Journal of Virology 58, 991-995. DILORENZO,T. P., TAM_SEN,A., AERAMSON,A. L. & STEINBERG,B. M. (1992). Human papiliomavirus type 6a DNA in the lung carcinoma of a patient with recurrent laryngeal papiUomatosis is characterized by a partial duplication. Journal of General Virology 73, 423-428. DI LucA, D., CASELLI, E., MONINL P., ROTOLA, A., SAVIOLI,A. & CASsAI, E. (1989). Episomal HPV 16 D N A isolated from a cervical carcinoma presents a partial duplication of the early region. Virus Research 14, 49-55. DORST, M., GlSSMANN,L., IKENBERG,H. & ztm HAUSEN,H. (1983). A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proceedings of the National Academy of Sciences, U.S.A. 80, 38123815. FARR, A., WANG, H., KAsrmR, M. S. & ROMAN, A. (1991). Relative enhancer activity and transforming potential of authentic human papillomavirus type 6 genomes from benign and malignant lesions. Journal of General Virology 72, 519-526. GISSMANN, L. & ZUR HAUSEN,H. (1980). Partial characterization of viral DNA from human genital warts (condylomata acuminata). International Journal of Cancer 25, 605-609. GlSSMANN,L., DE VILLmRS,E.-M. & Ztm HAUSEN,H. (1982). Analysis of human genital warts (condylomata acuminata) and other genital tumours for human papillomavirus type 6 DNA. International Journal of Cancer 29, 143-146. GhSSVa~NN, L., WOLNIK, L., IKENBERG, H., KOLDOVSKY, U., SCltNORCH,H. G. & ZUR HAUSEN,H. (1983). Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proceedingsof the NationalAcademy of Sciences, U.S.A. 80, 560-563.

3153

GRUSSENDORF, E.-I. & B~R, T. (1977). Condylomata acuminata associated with morbus Bowen (carcinoma in situ). Dermatologica 155, 50-58. GRUSSENDORF, E.-I. & GAHLEN, W. (1974). Morbus Bowen bei Condylomata acuminata. Zur Frage der M6glichkeit virusbedingter Tumorinduktion. Hautarzt 25, 443-447. GRUSSENI~RF-CONEN, E.-I., DEUTZ, F.-J. & DE VILLIERS, E.-M. (1987). Detection of human papiUomavirus-6 in primary carcinoma of the urethra in men. Cancer 60, 1832-1835. KASHER, M. S. & ROMAN, A. (1988). Characterization of human papillomavirus type 6b DNA isolated from an invasive squamous carcinoma of the vulva. Virology 165, 225-233. KULKE, R., GROSS, G. E. & PFISTER, H. (1989). Duplication of enhancer sequences in human papillomavirus 6 from condylomas of the mamilla. Virology 173, 284-290. OKAGAKI,T., CLARK,B. A., ZACHOW,K. R., TWlGGS, L. B., OSTROW, R. S., PASS, F. & FARAS, A. J. (1984). Presence of human papillomavirus in verrucous carcinoma (Ackermann) of the vagina. Archives of Pathology and Laboratory Medicine 108, 567-570. ORTH, G., FAVRE,M., BREITBURD,F., CROISSANT,O., JABLONSKA,S., OBALEK, S., JARZABEK-CHORZELSKA,M. & RZESA, G. (1980). Epidermodysplasia verruciformis: a model for the role of papillomaviruses in human cancer. In Viruses in Naturally Occurring Cancers, Cold Spring Harbor Cell Proliferation Conference 7, 259-282. Edited by M. Essex, G. Todaro & H. zur Hausen. New York: Cold Spring Harbor Laboratory. PFISTER, H. (1990). Properties of the virions and classification. In Papillomavirusesand Human Cancer, p. 2. Edited by H. Pfister. Boca Raton: CRC Press. R m ~ o , R. F., GROFF, D. E., CHIRIKJIAN,J. G. & LANCASTER,W. D. (1986a). Isolation and characterization of a novel human papillomavirus type 6 DNA from an invasive vulvar carcinoma. Journal of Virology 57, 353-356. RANDO, R. F., LANCASTER,W. D., HAN, P. & LOPEZ, C. (1986b). The noncoding region of HPV-6vc contains two distinct transcriptional enhancing elements. Virology 155, 546-556. SAIKI, R. K., SCHARF,S., FALOONA,F., MULLIS, K. B., HORN, G. T., ERLICH, H. A. & ARNHEIM,N. (1985). Enzymatic amplification offlglobin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350-1354. SCHEURLEN, W., STREMLAU,A., GlSSMANN,L., H6HN, D., ZENNER, H.-P. & ZURHAUSEN,H. (1986). Rearranged HPV 16 molecules in an anal and in a laryngeal carcinoma. InternationalJournalof Cancer 38, 671q176. SCHWARZ,E., DfJRST,M., DEMANKOWSKI,C., LATTERMANN,O., ZECH, R., WOLFSPERGER,E., SUHAI, S. & ZUR HAUSEN,H. (1983). DNA sequence and genome organization of genital human papillomavirus type 6b. EMBO Journal 2, 2341-2348. SLrrroN, G. P., STEHLMANN,F. B., ErmLICH, C. E. & ROMAN,A. (1987). Human papillomavirus deoxyribonucleic acid in lesions of the female genital tract: evidence for type 6/11 in squamous carcinoma of the vulva. Obstetrics and Gynecology 70, 564-568. Wu, T.-C. & MOUNTS,P. (1988). Transcriptional regulatory elements in the noncoding region of human papillomavirus type 6. Journalof Virology 62, 4722-4729. ZUR HAOSEN,H. & SCHNEIDER,A. (1987). The role of papillomaviruses in human anogenital cancers. In The Papovaviridae, vol. 2, pp. 245263. Edited by N. Salzman & P. M. Howley. New York: Plenum Press.

(Received 22 July 1992; Accepted 24 August 1992)